RESUMO
An oral pro-drug of acyclovir, 2-amino-9-(2-hydroxyethoxymethyl)-9H-purine (desciclovir) was evaluated in an open study comprising of 20 patients with herpes zoster. The clinical effects were comparable to those obtained with oral and intravenous acyclovir, even with a dosage of only 125 mg thrice daily. There was adequate absorption though considerable individual variation occurred. No effects of concomitant food intake were demonstrated. The finding of possible impaired conversion of desciclovir to acyclovir in one patient was unexplained and deserves attention in future studies. Likewise, more studies are needed to understand the occurrence of transient high peak plasma concentrations of acyclovir. Side-effects other than those already known with the use of acyclovir, namely reversible tubular damage, were not observed.
Assuntos
Aciclovir/análogos & derivados , Antivirais/uso terapêutico , Herpes Zoster/tratamento farmacológico , Aciclovir/farmacocinética , Aciclovir/uso terapêutico , Idoso , Antivirais/farmacocinética , Alimentos , Meia-Vida , Herpes Zoster/urina , Humanos , Testes de Função Renal , Pessoa de Meia-IdadeRESUMO
A study of the cytology of the urinary sediment in 43 patients with known viral diseases has revealed a variety of inclusion-bearing cells in 28.The morphology of the cells suggest that the changes recorded may be due to the viral infections, at least in some instances, bearing in mind the findings of workers quoted in our 1964 report that cellular changes very similar to those induced by virus infections can be initiated by non-viral stimuli. Multinucleate giant cells are occasionally found in chickenpox, measles, herpes simplex infection, and in mumps.
